Communicators

are winners!

More News

25.11.2024
BioNxt Announces Enhanced Sublingual Product Development Pipeline with Innovative Solutions for Autoimmune Diseases and Longevity
29.10.2024
BioNxt Announces National Level Patent Filings for Sublingual Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases
07.10.2024
Terry Lynch Joins BioNxt As Capital Markets Advisor
26.09.2024
BioNxt Provides Update on Cladribine Program for Multiple Sclerosis
09.09.2024
BioNxt Receives Positive International Examination Report From the European Patent Office for Broad Patent Application for Sublingual Delivery of Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases
15.08.2024
BioNxt Signs Letter of Intent with Gen-Plus GmbH & Co KG for Potential Business Collaborations
17.07.2024
BioNxt Signs Statement of Work with International Contract Research, Development, And Manufacturing Organization for Cladribine ODF Development
09.07.2024
BioNxt Signs Master Services Agreement with International Contract Research, Development, and Manufacturing Organization
18.03.2024
BioNxt Reports Commercialization of ODF Cladribine Product for MS Next Steps
13.03.2024
BioNxt Reports Successful Results From ODF Cladribine PK Study